1. Home
  2. BOF vs XLO Comparison

BOF vs XLO Comparison

Compare BOF & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BranchOut Food Inc.

BOF

BranchOut Food Inc.

HOLD

Current Price

$4.67

Market Cap

49.6M

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.83

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOF
XLO
Founded
2017
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.6M
49.8M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
BOF
XLO
Price
$4.67
$8.83
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
129.8K
26.9K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
31.33
N/A
EPS
N/A
N/A
Revenue
$3,184,018.00
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
258.20
589.88
52 Week Low
$1.93
$0.46
52 Week High
$4.95
$9.30

Technical Indicators

Market Signals
Indicator
BOF
XLO
Relative Strength Index (RSI) 69.03 63.66
Support Level $2.92 $7.47
Resistance Level $4.86 $8.97
Average True Range (ATR) 0.35 0.50
MACD 0.11 0.08
Stochastic Oscillator 86.43 79.80

Price Performance

Historical Comparison
BOF
XLO

About BOF BranchOut Food Inc.

Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: